Informed consent should be obtained from patients to use products (skin substitutes) and dressings containing biological material

Journal of Medical Ethics

Volumn 31, Issue 1, 2005, Pages 2-6

  Enoch, Stuart ^a,c   Shaaban, H ^b   Dunn, K W ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOBRANE; BIOLOGICAL PRODUCT; BIOMATERIAL; CALCIUM ALGINATE; CHITOSAN; DUODERM; JELONET; POLYURETHAN;

ANIMAL WELFARE; ARTICLE; AWARENESS; BANDAGE; CONSULTATION; CONTROLLED STUDY; DISEASE TRANSMISSION; HEALTH BEHAVIOR; HEALTH CARE FACILITY; HEALTH PRACTITIONER; HEALTH SURVEY; HUMAN; INFORMED CONSENT; LAW SUIT; MEDICAL SPECIALIST; PATIENT INFORMATION; POPULATION RESEARCH; PRION DISEASE; QUESTIONNAIRE; RELIGIOUS GROUP; UNITED KINGDOM; VIRUS TRANSMISSION;

EMPIRICAL APPROACH; HEALTH CARE AND PUBLIC HEALTH; RELIGIOUS APPROACH;

ATTITUDE TO HEALTH; BANDAGES; BIOCOMPATIBLE MATERIALS; GREAT BRITAIN; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PERSONNEL; HUMANS; INFORMED CONSENT; RELIGION AND MEDICINE; SKIN, ARTIFICIAL;

EID: 13444265162     PISSN: 03066800     EISSN: None     Source Type: Journal    
DOI: 10.1136/jme.2003.005272     Document Type: Article

References (23)

1. Ersek RA, Hachen HJ. Porcine xenografts in the treatment of pressure ulcers. Ann Plast Surg 1980;5:464-70.
2. Hansbrough JF, Franco ES. Skin replacements. Clinics in Plast Surg 1998;25:407-21.
3. Pruitt BA. The evolutionary development of biologic dressings and skin substitutes. J Burn Care and Rehab 1997; 18 S2-55.
4. Maral T, Borman H, Arslan H, et al. Effectiveness of human amnion preserved long-term in glycerol as a temporary biological dressing. Burns 1999;25:625-35.
5. Pruitt Jr BA, Curreri WC. The burn wound and its care. Arch Surg 1971;103:461-8.
6. Shakespeare P, Shakespeare V. Survey: use of skin substitute materials in UK burns treatment centres. Editorial. Burns 2002;28:295-7.
7. Kearney JN. Clinical evaluation of skin substitutes. Burns 2001;27:545-51.
8. Shakespeare P. Skin substitutes: benefits and costs. Burns 2001;27:7-8.
9. The UK population: by religion, April 2001; Source: Office for National Statistics, Census, April 2001. http://www.statistics.gov.uk./census2001/profiles/commentaries/ ethnicity.asp#ethnic (accessed 9 June 2004).
10. Wolf DL, Capozzi A, Pennisi VR. Evaluation of biologic dressings. Ann Plast Surg 1980;5:186-90.
11. Sheridan RL, Tompkins RG. Skin substitutes in burns. Burns 1999;25:97-103.
12. Lee HK. Tissue-engineered Human living Skin Substitutes: Development and Clinical Application. Yonsei Med J 2000;41:774-9.
13. Kealley GP. Disease transmission by means of allograft. J Burn Care Rehabil 1997;18:10-11.
14. Grant I. Ethical issues in burn care. Burns 1999;25:307-15.
15. Consent to treatment. The Medical Defence Union 3, 1996.
16. Herbert P. Due care and informed consent: doing right. Oxford University Press, 1996:84.
17. Consent to investigation and treatment. Seeking patients' consent: the ethical considerations, November 1998. http://www.gmc-uk.org./standards/default.htm (accessed 9 June 2004).
18. NHS Circular, Good Practice in Consent, 2001. http://www.doh.gov.uk/assetRoot/04/01/90/61/04019061.pdf
19. Freedom of thought, conscience and religion. Human Rights Act, 1998, Chapter 42, Schedules, Article 9. http://www.hmso.gov.uk/acts/acts1998/80042-d.htm (accessed 9 June 2004).
20. Andrews NJ, Farrington CP, Ward HJT, et al. Deaths from variant Creutzfeldt-Jakob disease in the UK. Lancet 2003;361:751-52.
21. Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that "new variant" CJD is caused by the BSE agent. Nature 1997;389:498-501.
22. Dolynchuk K, Hull P, Guenther L, et al. The role of Apligraf in the treatment of venous leg ulcers. Ostomy/Wound management 1999;45:34-43.
23. McKintosh E, Tabrizi SJ, Collinge J. Prion diseases. J Neurovirol 2003;9:183-93.